Novavax, Inc.
Novavax, Inc. (NVAX) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NVAX · as of Jun 8, 2026
Key Statistics
Explore Novavax, Inc. Data
nvax stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 23 · Buy rate: 73.9%
The NVAX analyst consensus is Buy, based on ratings from 23 Wall Street analysts over the past 3 months. The average 12-month price target is $18.00, representing +94.49% upside from the current price of $9.26.
Competitors & Peers
nvax competitorsNVAX
CVAC
NKTR
NTLA
ORIC
PGENStock Performance
Full HistoryAbout Novavax, Inc.
Novavax, Inc. a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine …
what is novavax, inc. · nvax stock overview · novavax, inc. company profile · who is novavax, inc. ceo · nvax NASDAQ · novavax, inc. headquarters · novavax, inc. business segments
About Stock Overview & Key Data
Novavax, Inc. (NVAX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Dec 5, 1995. As of the latest trading session, NVAX stock price is $9.26, with a market capitalization of $1.5B. The stock has returned +26.59% over the past 12 months and +39.58% year-to-date.
According to 23 Wall Street analysts, the consensus rating for Novavax, Inc. stock is Buy, with an average 12-month price target of $18.00. In fiscal year 2025, Novavax, Inc. reported revenue of $1.1B and net income of $440.3M. For detailed data — including Novavax, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Novavax, Inc. (NVAX) stock price is $9.26. The stock is traded on NASDAQ under the ticker symbol NVAX. The 52-week range is $6.13 – $11.97.